Sigilon Therapeutics Inc Revenue Growth Rates (SGTX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Sigilon Therapeutics Inc   (NASDAQ: SGTX)
 

SGTX's Revenue Growth by Quarter and Year

Sigilon Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SGTX Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter December -
3rd Quarter September -
2nd Quarter June 5.90
1st Quarter March 4.86
FY 10.76





SGTX Revenue second quarter 2023 Y/Y Growth Comment
Sigilon Therapeutics Inc achieved in the second quarter 2023, above Company average Revenue surge of 104.86% year on year, to $ 5.90 millions.

Looking into second quarter 2023 results within Major Pharmaceutical Preparations industry 53 other companies have achieved higher Revenue growth. While Sigilon Therapeutics Inc ' s Revenue doubling of 104.86% ranks overall at the positon no. 258 in the second quarter 2023.


SGTX Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter December - 32.66 % -47.07 % -
3rd Quarter September - 117.95 % -53.57 % -
2nd Quarter June 104.86 % 6.67 % 38.46 % -
1st Quarter March 53.31 % 7.09 % -14.7 % -
FY   - 34.79 % -28.25 % -

Financial Statements
Sigilon Therapeutics Inc 's second quarter 2023 Revenue $ 5.90 millions SGTX's Income Statement
Sigilon Therapeutics Inc 's second quarter 2022 Revenue $ 2.88 millions Quarterly SGTX's Income Statement


SGTX Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter December - -37.88 % 2.05 % -10.48 %
3rd Quarter September - 47.57 % -27.78 % 115.38 %
2nd Quarter June 21.4 % -9.15 % -8.78 % -43.8 %
1st Quarter March 84.09 % 59.3 % -21.28 % -
FY (Year on Year)   - 34.79 % -28.25 % -


Back to SGTX Growth rate Comparisons >> Back to SGTX Growth rate Comparisons >>


Revenue second quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #54
Healthcare Sector #83
Overall #258

Revenue Y/Y Growth Statistics
High Average Low
118.39 % 53.83 % 6.62 %
(Sep 30 2022)   (Jun 30 2022)
Revenue second quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #54
Healthcare Sector #83
Overall #258
Revenue Y/Y Growth Statistics
High Average Low
118.39 % 53.83 % 6.62 %
(Sep 30 2022)   (Jun 30 2022)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Sigilon Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
83.74 % 14.51 % -37.82 %
(Mar 31 2023)  


SGTX's II. Quarter Q/Q Revenue Comment
Sigilon Therapeutics Inc achieved in the II. Quarter 2023 above company average sequential Revenue jump of 21.4%, to $ 5.90 millions, from $4.86 millions in the first quarter.

Within Major Pharmaceutical Preparations industry 77 other companies have achieved higher Revenue quarter on quarter growth. While Sigilon Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 614.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #78
Healthcare Sector #153
Overall #614
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #78
Healthcare Sector #153
Overall #614
Revenue Q/Q Growth Statistics
High Average Low
83.74 % 14.51 % -37.82 %
(Mar 31 2023)  


SGTX's II. Quarter Q/Q Revenue Comment
Sigilon Therapeutics Inc achieved in the II. Quarter 2023 above company average sequential Revenue jump of 21.4%, to $ 5.90 millions, from $4.86 millions in the first quarter.

Within Major Pharmaceutical Preparations industry 77 other companies have achieved higher Revenue quarter on quarter growth. While Sigilon Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 614.


Sigilon Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)
Cumulative Revenue 12 Months Ending $ 17.65 $ 14.64 $ 12.94 $ 12.29 $ 9.99
Y / Y Revenue Growth (TTM) 76.81 % 49.27 % 34.85 % 8.14 % -26.68 %
Year on Year Revenue Growth Overall Ranking # 646 # 363 # 512 # 0 # 0
Seqeuential Revenue Change (TTM) 20.61 % 13.08 % 5.32 % 23.08 % 1.83 %
Seq. Revenue Growth (TTM) Overall Ranking # 2405 # 1522 # 2011 # 269 # 2368


Cumulative Revenue growth Comment
With 76.81% annual Revenue growth, Sigilon Therapeutics Inc would report a record annual Revenue growth if the fiscal year would end on Jun 30 2023.

In the Healthcare sector 157 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 363 to 646.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 137
Healthcare Sector # 158
Overall # 646

Revenue TTM Y/Y Growth Statistics
High Average Low
76.81 %
 53.64 %
34.85 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 137
Sector # 362
S&P 500 # 2405
Cumulative Revenue growth Comment
With 76.81% annual Revenue growth, Sigilon Therapeutics Inc would report a record annual Revenue growth if the fiscal year would end on Jun 30 2023.

In the Healthcare sector 157 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 363 to 646.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 137
Healthcare Sector # 158
Overall # 646

Revenue TTM Y/Y Growth Statistics
High Average Low
76.81 %
53.64 %
34.85 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 137
Sector # 362
S&P 500 # 2405




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
SGTX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Jun 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2023
Avricore Health Inc 181.54%$ 181.542 millions
2seventy Bio Inc 167.38%$ 167.379 millions
Clearside Biomedical Inc 165.10%$ 165.104 millions
Kiniksa Pharmaceuticals International Plc164.99%$ 164.990 millions
Igc Pharma Inc 161.79%$ 161.792 millions
Bicycle Therapeutics Plc160.32%$ 160.324 millions
Mannkind Corporation157.28%$ 157.283 millions
Transmedics Group Inc 155.66%$ 155.665 millions
Mirati Therapeutics Inc 155.32%$ 155.315 millions
Tango Therapeutics Inc 152.95%$ 152.954 millions
Emmaus Life Sciences Inc 150.97%$ 150.968 millions
Mersana Therapeutics inc 148.69%$ 148.693 millions
Evoke Pharma Inc 144.99%$ 144.994 millions
Agile Therapeutics Inc144.40%$ 144.403 millions
Harpoon Therapeutics Inc 143.54%$ 143.538 millions
Chinook Therapeutics Inc 141.15%$ 141.148 millions
Ensysce Biosciences Inc 136.41%$ 136.405 millions
Novavax inc 128.28%$ 128.278 millions
Orchestra Biomed Holdings Inc 128.18%$ 128.180 millions
Impel Pharmaceuticals Inc 127.04%$ 127.042 millions
Crinetics Pharmaceuticals Inc 125.06%$ 125.057 millions
Alkermes Plc 123.52%$ 123.517 millions
Invo Fertility Inc 116.17%$ 116.171 millions
Comera Life Sciences Holdings Inc 114.72%$ 114.723 millions
Mirum Pharmaceuticals Inc 114.46%$ 114.465 millions
Miromatrix Medical inc 112.93%$ 112.925 millions
Arch Therapeutics Inc 112.31%$ 112.314 millions
Sintx Technologies Inc 111.67%$ 111.667 millions
Surmodics Inc 111.17%$ 111.165 millions
Palatin Technologies Inc 109.04%$ 109.038 millions


About Sigilon Therapeutics Inc Revenue Growth Rates (SGTX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Sigilon Therapeutics Inc (CIK 1821323).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001558370-23-013494
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Sigilon Therapeutics Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.